{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:28:57Z","timestamp":1789421337886,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ijrobp.2021.03.027","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T21:54:04Z","timestamp":1616190844000},"page":"93-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Toxicity at 1 Year After Stereotactic Body Radiation Therapy in 3 Fractions for Localized Prostate Cancer"],"prefix":"10.1016","volume":"111","author":[{"given":"Alessandro","family":"Magli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Farneti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Faiella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariaconsiglia","family":"Ferriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Landoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"de Paula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gomellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sanguineti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2021.03.027_bib0001","first-page":"583","article-title":"NCCN guidelines updates: Management of prostate cancer","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0002","series-title":"Prostate cancer","author":"Mottet","year":"2020"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0003","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate cancer: A systematic review and meta-analysis of over 6,000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0005","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0006","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.01097","article-title":"Hypofractionated radiation therapy for localized prostate cancer: An ASTRO, ASCO, and AUA evidence-based guideline","author":"Morgan","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0007","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2014.08.009","article-title":"A systematic review of hypofractionation for primary management of prostate cancer","volume":"68","author":"Koontz","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0008","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0009","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijrobp.2018.12.045","article-title":"Five-year outcomes of a phase 1 dose-escalation study using stereotactic body radiosurgery for patients with low-risk and intermediate-risk prostate cancer","volume":"104","author":"Zelefsky","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.radonc.2020.09.053","article-title":"Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control","volume":"154","author":"Levin-Epstein","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0011","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0360-3016(94)E0126-5","article-title":"Tables of equivalent dose in 2 Gy fractions: A simple application of the linear quadratic formula","volume":"31","author":"Barton","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0012","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.ijrobp.2009.07.1679","article-title":"Effects of prostate-rectum separation on rectal dose from external beam radiotherapy","volume":"76","author":"Susil","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0013","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/j.ijrobp.2012.01.023","article-title":"Pelvic normal tissue contouring guidelines for radiation therapy: A radiation therapy oncology group consensus panel atlas","volume":"83","author":"Gay","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0014","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ijrobp.2013.10.042","article-title":"Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer","volume":"88","author":"Ghadjar","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.radonc.2008.01.015","article-title":"Comparison of three strategies to delineate the bowel for whole pelvis IMRT of prostate cancer","volume":"88","author":"Sanguineti","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0016","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3389\/fonc.2020.00555","article-title":"Urinary morbidity in men treated with stereotactic body radiation therapy (SBRT) for localized prostate cancer following transurethral resection of the prostate (TURP)","volume":"10","author":"Pepin","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0017","first-page":"163","article-title":"Phase II two-stage single-arm clinical trials for testing toxicity levels","volume":"26","author":"Kim","year":"2019","journal-title":"Commun Stat Appl Methods"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0018","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","article-title":"Sample size tables for exact single-stage phase II designs","volume":"20","author":"A'Hern","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0019","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13014-018-1135-6","article-title":"A novel model to correlate hydrogel spacer placement, perirectal space creation, and rectum dosimetry in prostate stereotactic body radiotherapy","volume":"13","author":"Hwang","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0020","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.euo.2018.06.013","article-title":"Phase 2 multicenter trial of heterogeneous-dosing stereotactic body radiotherapy for low- and intermediate-risk prostate cancer: 5-year outcomes","volume":"1","author":"Fuller","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0021","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1002\/cam4.2966","article-title":"Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results","volume":"9","author":"Zilli","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0022","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/cncr.26699","article-title":"Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial","volume":"118","author":"McBride","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0023","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","article-title":"Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: Survival and toxicity endpoints","volume":"102","author":"Meier","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0024","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.radonc.2020.04.013","article-title":"Dosimetric predictors of patient-reported toxicity after prostate stereotactic body radiotherapy: Analysis of full range of the dose-volume histogram using ensemble machine learning","volume":"148","author":"Pan","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0025","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ijrobp.2020.06.002","article-title":"Urethra-sparing stereotactic body radiation therapy for prostate cancer: Quality assurance of a randomized phase 2 trial","volume":"108","author":"Jaccard","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0026","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.radonc.2009.08.004","article-title":"Dose-volume effects for normal tissues in external radiotherapy: Pelvis","volume":"93","author":"Fiorino","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0027","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3389\/fonc.2020.00786","article-title":"Development and validation of a comprehensive multivariate dosimetric model for predicting late genitourinary toxicity following prostate cancer stereotactic body radiotherapy","volume":"10","author":"Valle","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0028","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0360-3016(02)03828-2","article-title":"How low is the alpha\/beta ratio for prostate cancer?","volume":"55","author":"Wang","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0029","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0360-3016(03)00364-X","article-title":"How low is the alpha\/beta ratio for prostate cancer? In regard to Wang et al., IJROBP 2003;55:194-203","volume":"57","author":"Fowler","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.027_bib0030","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/sim.1611","article-title":"Confidence intervals for the effect of a prognostic factor after selection of an \u201coptimal\u201d cutpoint","volume":"23","author":"Hollander","year":"2004","journal-title":"Stat Med"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162100287X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162100287X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:53:44Z","timestamp":1759744424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162100287X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S036030162100287X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.03.027","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity at 1 Year After Stereotactic Body Radiation Therapy in 3 Fractions for Localized Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}